Savara (SVRA) Says Aironite Fails to Meet Primary Endpoint in Indie Phase 2 Clinical Study (Earlier)
Tweet Send to a Friend
Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced results from the INDIE study of Aironite (sodium nitrite ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
